Arginine deprivation therapy for malignant melanoma

Jung Ki Yoon, Arthur E. Frankel, Lynn G. Feun, Suhendan Ekmekcioglu, Kevin B. Kim

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalClinical Pharmacology: Advances and Applications
Volume5
Issue number1
DOIs
StatePublished - Dec 21 2012

Keywords

  • Arginine deprivation
  • Argininosuccinate synthetase
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Arginine deprivation therapy for malignant melanoma'. Together they form a unique fingerprint.

  • Cite this